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Abstract
Parathyroidectomy (PTX) may cause low levels of PTH, leading to an excessive reduction of
bone turnover, which is associated with poor outcomes in dialysis patients, including vascular
calcification (VC). We aimed to prospectively investigate the impact of PTX on bone remodel-
ing and its potential consequence on the progression of VC in hemodialysis patients. In this
prospective study, 19 hemodialysis patients with severe secondary hyperparathyroidism
(sHPT) were evaluated. All patients underwent laboratorial tests and coronary tomography at
baseline and, 6 and 12 months after PTX; bone biopsy was performed at baseline and 12-
month. At baseline, all patients had increased PTH levels up to 2500 pg/mL and high turnover
bone disease in their bone biopsies. Fourteen (74%) patients had VC. During the follow-up,
there was a significant decrease of PTH at 6 and 12-month. At 12-month, 90% of the patients
evolved to low turnover bone disease. During the period of the hungry bone syndrome (first
6 months), no change of coronary calcium score was observed. However, calcium score
increased significantly thereafter (12th month). There was an association between VC pro-
gression and the severity of low turnover bone disease. In conclusion, the shift from high to
low turnover bone disease after PTX occurs in parallel to VC progression, contributing to the
understanding of the complex pathophysiology involving mineral metabolism and cardiovas-
cular disease in hemodialysis patients.
Introduction
Secondary hyperparathyroidism (sHPT) is a frequent and severe co-morbidity among chronic
kidney disease (CKD) patients, which is associated with cardiovascular disease, the main cause
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of the high rate of mortality in this population [1–6]. Although the current pharmacological
treatment has changed the course of sHPT, severe forms of the disease still require invasive
procedures, such as parathyroidectomy (PTX) [7]. In the setting of severe sHPT, PTX has been
considered to provide clinical short term benefits. However, the post-PTX resultant low levels
of PTH may lead to an excessive reduction of bone turnover, which is associated with poor
outcomes in dialysis patients. In fact, it has been demonstrated, in cross-sectional studies, that
low turnover bone disease is related to vascular calcification (VC) in both non-dialyzed and
dialyzed CKD patients [8–9]. It is well known that VC is a frequent and severe comorbidity in
CKD patients [10–14]. Of note, not only the presence of VC, but also its progression has been
associated with high mortality rate [15–16]. Thus, we aimed to prospectively investigate the
impact of PTX on bone remodeling and its potential consequence on the progression of VC in
hemodialysis patients.
Patients and methods patients
Hemodialysis patients referred to PTX due to severe sHPT were approached to participate in
this study. Exclusion criteria were age below 18 or above 65 years, presence of positive defer-
roxamine test, serious gastrointestinal disease, ethanol or drug abuse, active malignancy,
human immunodeficiency virus infection, chronic inflammatory disease, previous myocardial
revascularization, uncontrolled diabetes mellitus or hypertension, body weight greater than
100 kg, pregnancy or breast-feeding, and use of corticosteroids, antiarrhythmic or seizure
drugs. Nineteen out of 25 screened patients completed a 12-month follow-up. The reasons of
drop-out were: death (2 patients), persistent sHPT (2 patients), withdraw (1 patient) and lung
tuberculosis (1 patient). These patients were not different regarding baseline demographic,
laboratory, coronary tomography or bone biopsy characteristics from those who completed
the study.
The study was reviewed and approved by the Ethics Advisory Committee of the Federal
University of São Paulo (approval number: 0918/06). All patients gave written informed
consent.
Study protocol
This was a prospective study of 12 months. At the time of PTX (baseline), all patients under-
went an assessment of their clinical history, physical examination, laboratory tests, coronary
tomography and bone biopsy. Laboratory tests and coronary tomography were repeated at 6
and 12-month, and the bone biopsy at 12-month. During the follow-up, cumulative doses of
calcitriol and elemental calcium from calcium salts were recorded.
According to local protocol, patients were referred to PTX due to unsuccessful pharmaco-
logical therapy or the presence of severe bone pain, fractures and calciphylaxis. Total PTX fol-
lowed by parasternal autotransplantation was performed as described elsewhere [17].
Multislice coronary tomography
In order to evaluate VC, patients underwent coronary calcium quantification by multislice
computed tomography scanner (Somatrom Volum Zoom Siemens AG1, Erlhagen, Ger-
many) using a gantry rotation of 0.4s, collimation of 2.5mm (slice thickness), and reconstruc-
tion time of 6 frames per second. All obtained scans were analyzed using an Indigo 21
workstation (SGI, Mountain View, CA, USA) and a calcium threshold of 130 Housfield
Units was used. The images were scored by a single radiologist blinded to all clinical and bio-
chemical data of the patients. Total score was the sum of each coronary score, expressed in
modified Agatston Units (AU) [18]. Presence of VC was defined as coronary calcium score
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>10 AU. The absolute progression of VC, named as delta-calcium score, was calculated as the
difference between 12-month and baseline calcium score.
Bone biopsy
Baseline and 12-month bone specimens were obtained from the iliac crest. The second biopsy
was performed in the contralateral site to avoid interference of repair processes from the previ-
ous biopsy. The procedure was conducted using a trephine with a 7-mm inner diameter
adapted to an electrical drill (Gauthier Medical, Rochester, MN, USA). All patients were prela-
beled with oral tetracycline (20 mg/kg/d for 3 days) administered over 2 periods, 10 days apart.
Undecalcified bone fragments were submitted to specific histological technique, described
elsewhere [19]. Bone histomorphometric analysis was conducted using the semiautomatic
method contained in the Osteomeasure software (Osteometrics Inc, Atlanta, GA, USA). Histo-
morphometric parameters were those suggested by the American Society of Bone and Mineral
Research histomorphometry nomenclature committee [20]. Reference values (RV) used for
static parameters were obtained from local controls [21], whereas dynamic parameters fol-
lowed those described elsewhere [22].
The following parameters were analyzed: trabecular bone volume/total bone volume (BV/
TV; RV = 24 ± 6.1% for men and 21.8 ± 7.2% for women), osteoid volume/trabecular bone vol-
ume (OV/BV; RV = 2.9 ± 2.7% for men and 1.55 ± 1.9% for women), trabecular thickness
(TbTh; RV = 127.9 ± 29.7 μm for men and 126 ± 28.8 μm for women), trabecular separation
(TbSp; RV = 420.6 ± 124.1 μm for men and 498.3 ± 195.9 μm for women), trabecular number
(TbN; RV = 1.89 ± 0.42 N/mm for men and 1.76 ± 0.52 N/mm for women), osteoblast surface/
bone surface (Ob.S/BS; RV = 1.2 ± 1.4% for men and 1.2 ± 3.2% for women), osteoclast sur-
face/bone surface (Oc.S/BS; RV = 0.03 ± 0.11% for men and 0.03 ± 0.06% for women), eroded
surface/bone surface (ES/BS; RV = 2.3 ± 2.4% for men and 1.75 ± 1.21% for women), marrow
fibrosis volume/total bone volume (Fb.V/TV; RV = 0%), bone formation rate/bone surface
(BFR/BS; RV = 0.13± 0.07 μm3/μm2/d for men and 0.07 ± 0.03 μm3/μm2/d for women), miner-
alization lag time (Mlt; RV = 23.7 ± 2.7 days for men and 21.3 ± 2.3 days for women). Patients
were classified according to BFR/BS into high turnover bone disease (HTBD = BFR/BS values
greater than 1 standard deviation (SD) above the normal range) or low turnover bone disease
(LTBD = BFR/BS values greater than 1 SD below the normal range) [23]. Patients whose tra-
becular bone surface did not uptake tetracycline were classified as having very low turnover
bone disease (VLTBD).
Laboratory analyses
Blood samples were drawn after an overnight fast of at least 12 hours for determining the fol-
lowing laboratory tests: ionized calcium, phosphorus, total alkaline phosphatase (35–104 U/L
for females and 40–129 U/L for males), intact PTH (Immulite; DPC-Biermann, Bad Nauheim,
Germany, 10–65 pg/ml), intact fibroblast growth factor 23 (FGF23; Elisa assay, Kainos, Japan)
at baseline and 12-month.
Statistical analyses
Mean and standard deviation, median and interquartile range or frequencies were calculated
for all variables. Comparisons of continuous variables were done by Student´s or Wilcoxon
tests according to the variable distribution. In order to evaluate the changes of calcium score in
the patients with VC at baseline, a repeated measure design was used considering three periods
(baseline, 6 and 12-month) as the main effect. For those with normal distribution, test for time
was conducted using ANOVA for repeated measures via MIXED procedure, followed by
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adjusted Tukey test for multiple comparisons. When the variable did not have normal distri-
bution, the same design was used fitting a generalized linear model via GENMOD procedure
with gamma distribution and link reciprocal. Multiple comparisons in this case were made
using DIFF option from the GENMOD procedure [24]. Spearman´s correlation test was
applied to evaluate the association between delta-calcium score and cumulative doses of ele-
mental calcium and calcitriol. All procedures were made using SAS for Windows (version 9.2;
SAS, Cary, NC, USA), and p value < 0.05 was considered statistically significant.
Results
Demographic, laboratory, bone biopsy and coronary tomography parameters at baseline, 6
and 12-month from the 19 patients who completed the study are shown in Table 1. Patients
were relatively young, white women, long time on dialysis and 63% with BMI< 23 kg/m2.
Most of the patients had hypertension (68%) and none had diabetes as comorbid condition.
Six patients were not submitted to autotransplantation after PTX due to the absence of suitable
parathyroid tissue.
At baseline, laboratory data are in accordance with severe sHPT, with increased PTH levels
up to 2500 pg/mL. At 6 and 12-month, patients had significant lower levels of serum ionized
calcium, alkaline phosphatase and PTH compared to baseline. Phosphorus levels had a signifi-
cant decrease only at 6-month while FGF23 remained stable.
Regarding renal osteodystrophy (ROD), at the baseline, all patients had HTBD, as shown
by the increased values of osteoid volume, osteoblastic, eroded and osteoclastic surfaces, fibro-
sis volume and bone formation rate. Of note, aluminum deposits on bone surface were not
detected. At 12-month, there was a significant decrease of all those histomorphometric param-
eters, while an increase of trabecular thickness and mineralization lag time, and a trend to an
increase of bone volume (p = 0.09) were observed. According to the ROD diagnose, 10% of the
patients evolved to normal bone turnover, 10% to LTBD and 80% to VLTBD (Fig 1).
At baseline, 5 out of 19 patients (26%) had no VC, remaining unchanged until the end of
the study. Regarding clinical, demographic and laboratorial parameters, this group was similar
to the 14 calcified patients. Of note, progression was observed only in patients who had VC at
baseline (n = 14). In this calcified group there was no significant difference between calcium
score at baseline and 6-month. However, a significant increase of calcium score was observed
at 12-month when compared to baseline and 6-month. Fig 2 shows the changes of calcium
score and alkaline phosphatase of these patients during the study. Total alkaline phosphatase
decreased during the first 6 months [from 551 (355–788) at baseline to 96 (79–143) U/L at
6-month (p = 0.01)], while calcium score increased during the last 6 months after PTX [from
552 (65–1308) at 6-month to 772 (90–1397) AU at 12-month; p = 0.02]. The doses of elemental
calcium and calcitriol in the first 6 months were significantly higher than those ones in the last
6 months [241 (188–244) vs. 135 (73–252) g; p<0.01 and 257 (192–381) vs. 34.3 (5.2–101)
mcg, respectively; p = 0.001]. Of note, no correlation was found between delta-calcium score
and the cumulative doses of both drugs. In the patients with VC progression, 14% evolved to
normal bone turnover, 14% to LTBD and 72% to VLTBD. The delta-calcium score of the
VLTBD compared to normal plus LTBD groups was significantly higher [197 AU (53–396) vs.
46 AU (14–128), respectively; p = 0.04] (Fig 3).
Discussion
In the current study, we could observe that the shift from high to low turnover bone disease
after PTX was related to the progression of VC in hemodialysis patients.
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Parathyroidectomy has been still proposed as a useful treatment for severe sHPT, even after
the introduction of drugs such as cinacalcet and selective activators of vitamin D receptor.
Parathyroid hormone levels have been shown to be low shortly after PTX [25,26]. In the pres-
ent study, the PTH values at 12-month were low and similar to those reported by Fothering-
ham et al [26]. These authors described a cohort of 252 CKD patients whose median of PTH
levels were 139 (interquartile range 46–420) pg/mL after 5 years following PTX. Although clin-
ical short term benefits of PTX have been unquestionable, the drastic decrease of PTH levels,
even in those patients underwent autotransplantation, may lead to an extreme reduction of
bone turnover [8]. It is well known that PTH levels lower than 150 pg/mL is associated with
LTBD in patients on dialysis [27–29]. In fact, in the present study> 90% reduction of PTH
levels occurred along with all but two patients who developed LTBD in the period of one year
Table 1. Demographic, coronary tomography, laboratory and bone histomorphometry data of 19 patients.
Baseline 6-month 12-month
Demographic characteristics
Age (y) 45 ± 11
Women n (%) 12 (63)
White n (%) 13 (68)
Time on hemodialysis (mo) 105 ± 46
PTX+autotransplantation (%) 68
Body mass index (Kg/m2) 23.1 ± 3.8 23.1 ± 3.6
Laboratory
Ionized calcium (mmol/L) 1.33 ± 0.10 1.21 ± 0.11a 1.19 ± 0.11 a
Phosphorus (mg/dl) 6.8 ± 2.1 4.9 ± 2.1a 5.3 ± 1.6
Alkaline phosphatase (U/L) 565 (377–984) 107 (82–146)a 106 (73–126) a
Intact PTH (pg/ml) 2152 (1638–2500) 47 (10–71)a 58 (12–117) a
FGF23 (pg/ml) 8583 (2879–59283) 6701(134–18396)
Bone Histomorphometry
BV/TV (%) 11.3 (7.7–16) 14.9 (8.5–20)
TbTh (μm) 99.3 (85.7–127.3) 137.8 (114.5–156) a
TbSp (%) 750 (553–1155) 796 (514–1365)
TbN (n) 1.1 (0.7–1.5) 0.6 (0.67–1.45)
OV/BV (%) 8.9 (5.7–14) 7.2 (2–8.8) a
Ob.S/BS (%) 7.9 (6.8–18.6) 1.04 (0.5–1.7) a
ES/BS (%) 16.1 (13.2–20.4) 1.7 (0.9–3.5) a
Oc.S/BS (%) 5.9 (4.4–6.8) 0.3 (0.1–0.6) a
Fb.V/TV (%) 5.1 (2–7.8) 0.01 (0–0.1) a
BFR/BS (μm3/ μm2/d) 0.16 (0.09–0.22) 0.006 (0.006–0.009) a
Mlt (d) 32 (21–52) 809 (466–809) a
Coronary Tomography
Calcium score (AU) 76 (2.2–996) 103 (2.2–1082) 122 (2.4–1160) a,b
Mean ±standard deviation, median and interquartile range or frequencies.
a: vs.baseline
b: vs. 6-month; p<0.05.
Abbreviations: PTX, parathyroidectomy; PTH, parathormone; FGF23, fibroblast growth factor 23; BV/TV, trabecular bone volume / total volume; TbTh,
trabecular thickness; TbSp, trabecular separation; TbN, trabecular number; OV/BV, osteoid volume / trabecular bone volume; Ob.S/BS, osteoblastic
surface / bone surface; ES/BS, eroded surface / bone surface; Oc.S/BS, osteoclastic surface / bone surface; Fb.V/TV, marrow fibrosis volume / total
volume; BFR/BS, bone formation rate / bone surface; Mlt, mineralization lag time
https://doi.org/10.1371/journal.pone.0174811.t001
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after PTX. Moreover, the shift from high to low bone turnover status was well documented.
After one year of PTX, the observed decrease of bone formation and resorption parameters,
e.g., paucity of cellularity, lacking of marrow fibrosis and the striking reduction of bone forma-
tion rate corroborate with the diagnosis of LTBD, as described elsewhere [8,30]. This exchange
in bone turnover patterns after PTX comprises a period of increasing bone formation in paral-
lel with cessation of bone resorption, named “hungry bone syndrome”, characterized by the
decrease of alkaline phosphatase, serum calcium and phosphorus levels, associated to
Fig 1. Evolution of bone turnover in the calcified and no calcified patients following PTX.
https://doi.org/10.1371/journal.pone.0174811.g001
Fig 2. Calcium score and alkaline phosphatase in hemodialysis patients with VC during 12 months
after parathyroidectomy (n = 14).
https://doi.org/10.1371/journal.pone.0174811.g002
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requirements of high doses of calcium salts and calcitriol [31]. In this cohort, the laboratorial
characteristics of this phenomenon could be observed in the first 6 months after PTX, accom-
panied by a significant decrease of alkaline phosphatase levels, as depicted in Fig 2.
In the first 6-month period, VC progression did not evolve even under the use of high
doses of calcium salts and calcitriol. This finding could be partially explained by the improve-
ment of bone tissue buffering capability, which favors the accretion of calcium and phosphorus
into the bone matrix. Interestingly, VC progression could be observed during the second 6
months after PTX, in which “hungry bone syndrome” has finished, as suggested by the nor-
malization of alkaline phosphatase. During this period, lesser but not low doses of calcium and
calcitriol are still necessary in order to maintain the serum calcium within the normal range.
This may have influenced the VC progression. However, this hypothesis could not be estab-
lished in this study, as no correlation was observed between the change of calcium score and
the cumulative doses of calcium and calcitriol.
An unquestionable contribution of this study to better understand the events formerly dis-
cussed was the availability of two consecutive bone biopsies. Although the association of LTBD
with VC has been suggested by London et al in a cross-sectional study [8], as far as we are con-
cerned, the present study is the first one to demonstrate prospectively this association. One
could speculate about the relationship between the exchange pattern of bone biopsy and VC.
In fact, the shift from HTBD to LTBD in parallel with VC progression could advocate this
hypothesis. Furthermore, once VC progression occurs only in the last 6-month period, e.g.,
after the cessation of the “hungry bone syndrome”, we could consider that LTBD has emerged
at this moment. Unfortunately, the lack of bone biopsy at 6-month does not allow us to con-
firm that hypothesis. Furthermore, we could demonstrate herein the association between the
Fig 3. Comparison of delta calcium score between very low (VLTBD) and normal/low (LTBD) turnover
bone disease groups.
https://doi.org/10.1371/journal.pone.0174811.g003
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severity of low turnover bone disease and the progression of VC. The finding of a subgroup of
patients with VLTBD and higher delta calcium score at 12-month, suggests that the lower
bone turnover the higher VC progression (Fig 3). It is important to mention that the absence
of tetracycline labels in the trabecular bone of patients with VLTBD could not be ascribed to
the failure of tetracycline intake, as we could find tetracycline double labels in the cortical bone
of these patients (data not shown).
The limitations of the current study rely on the relatively few patients enrolled into the
investigation which was due to the strict inclusion criteria (patients with severe sHPT referred
to PTX), and on the lack of a control group, once the maintenance of such a group of patients
without treatment would conflict to ethical issues.
In conclusion, in this study, the particular pattern of VC progression and the parallel associ-
ation with the decreasing bone turnover, observed after PTX, could add a contribution for the
understanding of the complex pathophysiology involving mineral metabolism and cardiovas-
cular disease in hemodialysis patients.
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